Latest News

Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency

– Safety and Efficacy Profile Consistent with Previously Reported Data – – Hemoglobin Increases >1.0 g/dL in 26 of 52 Patients Overall; Responses Remain Durable with Completion of Six Month Core Treatment Period –– Two Global Pivotal Trials in PK Deficiency on Track to Initiate in First Half of 2018 –ATLANTA, Dec. 10, 2017 -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) presented updated data today from its wholly owned pyruvate kinase-R (PKR) activator, AG-348, demonstrating its...

Published on .

Riassunto: Takeda e Seattle Genetics presenteranno dati positivi dello studio clinico di fase 3 ECHELON-1 per la valutazione di ADCETRIS® (brentuximab vedotin) nel linfoma di Hodgkin avanzato

CAMBRIDGE, Mass. & OSAKA, Giappone & BOTHELL, Wash.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) e Seattle Genetics, Inc. (NASDAQ: SGEN) hanno oggi annunciato che i dati dello studio clinico di fase 3 ECHELON-1 per la valutazione di ADCETRIS (brentuximab vedotin) come parte di un regime chemioterapico in combinazione di prima linea nel linfoma classico di Hodgkin avanzato e non trattato saranno presentati nel corso della sessione scientifica plenaria...

Published on .

Georgia Power restoration efforts to be largely completed Sunday

ATLANTA, Dec. 10, 2017 -- Georgia Power expects to have restoration efforts largely completed Sunday with crews in the field remaining focused on reconnecting all customers impacted by this weekend's severe winter weather which brought snowfall, freezing rain and ice throughout North Georgia. While weather conditions are improving today, many areas remain inaccessible due to heavy snowfall, fallen trees or blocked roads. Restoration teams are gaining access to some of the hardest-hit...

Published on .

Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Dec. 10, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company developing novel epigenetic therapies, today announced that two presentations reinforcing its commitment to identifying predictors of response to tazemetostat beyond EZH2 mutations will be featured at the 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) in Atlanta, Ga.These data from the company's ongoing Phase 2 clinical trial in non-Hodgkin lymphoma (NHL)...

Published on .

Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients

39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4high patient population receiving G100+pembrolizumab (potential predictive biomarker)Responses occur in both recurrent/refractory and treatment-naïve patient populationsData presented at ASH 2017Conference call Monday, December 11 at 8:00 a.m. ESTSEATTLE and SOUTH SAN FRANCISCO, Calif., Dec. 10, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today presented...

Published on .

Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia

– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation –– All nine evaluable patients with RAS wild-type achieved stable disease or better –– Preliminary data presented today at American Society of Hematology Annual Meeting –– More data, including progression-free survival in the RAS wild-type and RAS mutant subsets, expected in 2018 –SAN DIEGO, Dec. 10, 2017...

Published on .

Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A

ATLANTA--(BUSINESS WIRE)--Bioverativ Inc. (NASDAQ: BIVV) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announce the results of a new, post-hoc, longitudinal analysis of the pivotal Phase 3 A-LONG study and ASPIRE long-term extension study, showing that weekly prophylactic dosing with its extended half-life therapy ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein], marketed as Elocta® in Europe and the Middle East, has the potential to provide improved bleed...

Published on .

Study shows weekly prophylactic treatment with Elocta® resulted in bleed protection and target joint resolution in people with haemophilia A

Sun, Dec 10, 2017 15:02 CETSwedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) and  Bioverativ Inc. (NASDAQ: BIVV) today announce the results of a new, post-hoc, longitudinal analysis of the pivotal Phase 3 A-LONG study and ASPIRE long-term extension study, showing that weekly prophylactic dosing with its extended half-life therapy Elocta® (efmoroctocog alfa) marketed as ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] in the US, has the potential to provide improved bleed...

Published on .

Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

Sun, Dec 10, 2017 15:00 CETStockholm – December 10th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the first survival data were presented at the annual meeting of the American Society of Hematology from the phase II-study O-12-M1 in late-stage patients with Relapsed Refractory Multiple Myeloma (RRMM). Summary of key results presented The results show a median progression-free survival (PFS) of 5.7 months, a median overall survival (OS) of 20.7 months and an overall response...

Published on .

CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 10, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP) today announced the presentation of new data on CTX001, an investigational CRISPR gene-edited therapy for patients suffering from β-thalassemia and sickle cell disease. The data were discussed in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10th, 2017.“With CTX001, we are able to efficiently edit hematopoietic stem cells to achieve high levels of fetal...

Published on .